Mark A. Turco, MD, Appointed CEO of Field Medical to Drive Growth

Mark A. Turco, MD, Assumes Role as CEO of Field Medical

Field Medical, Inc., a pioneering firm in the development of second-generation pulsed field ablation (PFA) solutions for intricate cardiac conditions, has officially appointed Dr. Mark A. Turco as its new Chief Executive Officer. This announcement, made on March 16, 2026, signals a pivotal moment for the company as it seeks to enhance its operational capabilities and advance critical clinical programs.

Dr. Turco brings over three decades of extensive leadership experience across the cardiovascular medical technology landscape. His prior roles include significant positions within both startups and established medical device giants. Notably, he has skillfully guided clinical-stage companies through transformative phases, focusing on growth and sustainable strategies in the medical technology sector.

The appointment of Dr. Turco comes at a time when Field Medical is aiming to bolster its clinical programs, particularly in addressing complex ventricular and atrial arrhythmias. Ben Cannon, a board member of Field Medical and a part of the BioStar Capital and Cue Growth investment teams, expressed confidence in Dr. Turco's expertise. According to him, Dr. Turco's unique blend of experience as a cardiologist and his background in the medical device industry positions him perfectly to navigate Field Medical through its next phase of development.

"Mark's distinctive background equips him well to guide Field Medical through this next phase of growth," Cannon stated. As the company gears up to accelerate its clinical initiatives, Dr. Turco's executive experience will be crucial in advancing complex medical technologies—ensuring regulatory and commercialization success.

Before his current role, Dr. Turco served as President and CEO at JC Medical, Inc. Under his leadership, the company developed an innovative transcatheter aortic valve replacement (TAVR) system for patients with aortic regurgitation. This system was later acquired by Edwards Lifesciences in July 2024. His experience includes senior leadership positions at Medtronic and Covidien, where he was Vice President and Chief Medical Officer for vascular and neurovascular divisions. Most recently, he served as President and CEO of the Rhode Island Life Science Hub.

Dr. Turco's clinical insight as a board-certified interventional cardiologist adds depth to his leadership at Field Medical. Upon his appointment, he expressed his honor and excitement in joining the company at a crucial juncture. He stated, "The company has developed a unique PFA platform capable of significantly addressing critical unmet patient needs in the field of ventricular arrhythmias and atrial fibrillation. I am eager to work closely with the talented team at Field Medical as we advance our clinical programs and navigate the regulatory landscape to achieve our mission."

Founded in 2022, Field Medical is committed to innovating cardiac treatment. Its FieldForce Ablation System integrates a cutting-edge catheter design paired with proprietary FieldBending™ energy technology, aiming to provide safe and efficient treatment solutions. Furthermore, in 2024, the company was honored with Breakthrough Device Designation and entered the FDA TAP Pilot Program for its ventricular tachycardia indication. The successful VCAS trial's publication in Circulation in October 2025 marked another milestone in the company's journey.

As Field Medical sets its sights on advancing its operations and technologies under Dr. Turco's leadership, the medical community eagerly anticipates the contributions it will make to the field of cardiovascular health. For updates and more information, visit www.fieldmedicalinc.com or follow the company on LinkedIn, Twitter, and YouTube.

The FieldForce™ Ablation System currently remains an investigational device, regulated by federal law for investigational use only.